Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
Authors:
Open Access
- 1 January 2017
- journal article
- review article
- Published by XMLink in Journal of Breast Cancer
- Vol. 20 (4) , 321-326
Abstract
Yi Z, et al. J Breast Cancer. 2017 Dec;20(4):321-326. https://doi.org/10.4048/jbc.2017.20.4.321Keywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (D161100000816004)
This publication has 38 references indexed in Scilit:
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and femalesCA: A Cancer Journal for Clinicians, 2016
- Mechanisms of aromatase inhibitor resistanceNature Reviews Cancer, 2015
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology, 2014
- The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkersTherapeutic Advances in Medical Oncology, 2014
- Activating ESR1 mutations in hormone-resistant metastatic breast cancerNature Genetics, 2013
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisAdvances in Therapy, 2013
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyJournal of Clinical Investigation, 2011
- “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?Breast Cancer Research and Treatment, 2010